CYP2D6 deficiency, a factor in ecstasy related deaths?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 44 citations in OpenAlex.

1. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.Clinical pharmacokinetics · 2011
   Trial
2. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.Clinical pharmacokinetics · 2005
   Trial
3. Pharmacogenomics of 3,4-Methylenedioxymethamphetamine (MDMA): A Narrative Review of the Literature.Pharmaceutics · 2024
   Review
4. CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals.Pharmacogenetics and genomics · 2016
   Article
5. MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?Frontiers in genetics · 2012
   Article
6. Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview.Molecular neurobiology · 2009
   Review
7. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities.Psychopharmacology · 2004
   Review
8. Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.Clinical pharmacokinetics · 2004
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as